Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results
08 janv. 2024 08h30 HE
|
Neuronetics
MALVERN, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of...
Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory
18 déc. 2023 08h49 HE
|
Neuronetics
MALVERN, Pa., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
NeuroStar TMS Receives Expanded Regulatory Approval in Japan
04 déc. 2023 08h56 HE
|
Neuronetics
MALVERN, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics to Present at the 35th Annual Piper Sandler Healthcare Conference
15 nov. 2023 16h15 HE
|
Neuronetics
MALVERN, Pa., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements
13 nov. 2023 08h57 HE
|
Neuronetics
MALVERN, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage
09 nov. 2023 08h32 HE
|
Neuronetics
MALVERN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Reports Third Quarter 2023 Financial and Operating Results
07 nov. 2023 07h30 HE
|
Neuronetics
MALVERN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06 nov. 2023 16h30 HE
|
Neuronetics
MALVERN, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call
24 oct. 2023 08h30 HE
|
Neuronetics
MALVERN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Brain Stimulation Highlights Best Practices for Optimal TMS Treatment Outcomes
16 oct. 2023 08h56 HE
|
Neuronetics
MALVERN, Pa., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...